Tyra Biosciences, Inc. (NASDAQ:TYRA) Short Interest Update

Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report) saw a significant growth in short interest in May. As of May 15th, there was short interest totalling 5,100,000 shares, a growth of 17.2% from the April 30th total of 4,350,000 shares. Approximately 16.0% of the company's shares are short sold. Based on an average trading volume of 319,800 shares, the short-interest ratio is presently 15.9 days.

Institutional Investors Weigh In On Tyra Biosciences

Institutional investors have recently made changes to their positions in the stock. Rhumbline Advisers increased its position in Tyra Biosciences by 7.2% in the 1st quarter. Rhumbline Advisers now owns 28,081 shares of the company's stock valued at $261,000 after buying an additional 1,879 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Tyra Biosciences during the 1st quarter valued at approximately $324,000. Woodline Partners LP purchased a new stake in Tyra Biosciences in the first quarter worth $931,000. Goldman Sachs Group Inc. increased its holdings in Tyra Biosciences by 21.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 78,006 shares of the company's stock worth $725,000 after acquiring an additional 13,896 shares during the last quarter. Finally, Polar Asset Management Partners Inc. raised its position in shares of Tyra Biosciences by 27.1% in the first quarter. Polar Asset Management Partners Inc. now owns 141,241 shares of the company's stock valued at $1,314,000 after purchasing an additional 30,134 shares during the period. Institutional investors own 84.14% of the company's stock.

Wall Street Analysts Forecast Growth

TYRA has been the topic of several research reports. HC Wainwright restated a "buy" rating and set a $30.00 price objective on shares of Tyra Biosciences in a research note on Monday, March 31st. Wedbush restated an "outperform" rating and set a $30.00 price target on shares of Tyra Biosciences in a report on Friday, March 28th. Finally, Piper Sandler started coverage on Tyra Biosciences in a research report on Wednesday, May 21st. They set an "overweight" rating and a $33.00 price objective for the company. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $30.83.

Tyra Biosciences Stock Performance

NASDAQ TYRA traded up $0.50 on Friday, reaching $10.67. The company had a trading volume of 102,308 shares, compared to its average volume of 271,711. Tyra Biosciences has a 1-year low of $6.42 and a 1-year high of $29.60. The company's fifty day moving average is $9.28 and its 200-day moving average is $12.21. The firm has a market capitalization of $566.47 million, a price-to-earnings ratio of -6.63 and a beta of 1.07.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.49) by $0.02. On average, research analysts forecast that Tyra Biosciences will post -1.57 earnings per share for the current year.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.